Skip to main content

Advertisement

SpringerLink
Log in

Effect of androgen deprivation therapy on arterial stiffness and serum lipid profile changes in patients with prostate cancer: a prospective study of initial 6-month follow-up

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Background

To explore arterial stiffness during the administration of androgen deprivation therapy (ADT) in patients with prostate cancer (PCa), a new indicator, the cardio-ankle vascular index (CAVI), and serum lipid profile changes were monitored.

Methods

A prospective study assessed the changes in arterial stiffness using the CAVI and clinical laboratory variables among 58 men with prostate cancer treated with ADT for 6 months. Furthermore, patients who had a high risk of developing arterial stiffness after ADT were investigated.

Results

The whole cohort had no significant increase in arterial stiffness within 6 months after ADT, but 55.2 % of patients had an increased CAVI. Serum levels of total cholesterol, high-density-lipoprotein cholesterol (HDL-C), and low-density-lipoprotein cholesterol (LDL-C) increased significantly at 1 month after the start of ADT and maintained high values thereafter. At baseline, HDL-C was lower and LDL-C and LDL-C/HDL-C were higher in the group with than without an increased CAVI after 6 months of ADT administration.

Conclusions

Although the whole cohort did not show a significant change in arterial stiffness with ADT, some patients showed an increased arterial stiffness monitored with the CAVI. The balance between LDL-C and HDL-C, or LDL-C/HDL-C, might have an impact on the development of arterial stiffness after ADT administration. Thus, clinicians might be able to monitor PCa patients who have a high risk of development of arterial stiffness after ADT administration by referring to LDL-C/HDL-C levels.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Suzuki H, Kamiya N, Imamoto T et al (2008) Current topics and perspectives relating to hormone therapy for prostate cancer. Int J Clin Oncol 13:401–410

    Article  CAS  PubMed  Google Scholar 

  2. Kamiya N, Suzuki H, Nishimura K et al (2014) Development of nomogram to non-steroidal antiandrogen sequential alternation in prostate cancer for predictive model. Jpn J Clin Oncol 44:263–269

    Article  PubMed  Google Scholar 

  3. Imamoto T, Suzuki H, Utsumi T et al (2009) Association between serum sex hormone levels and prostate cancer: effect of prostate cancer on serum testosterone levels. Future Oncol 5:1005–1013

    Article  CAS  PubMed  Google Scholar 

  4. Kamiya N, Suzuki H, Ueda T et al (2014) Clinical outcomes by relative docetaxel dose and dose intensity as chemotherapy for Japanese patients with castration-resistant prostate cancer: a retrospective multi-institutional collaborative study. Int J Clin Oncol 19:157–164

    Article  CAS  PubMed  Google Scholar 

  5. Shahinian VB, Kuo YF, Freeman JL et al (2005) Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 103:1615–1624

    Article  CAS  PubMed  Google Scholar 

  6. Allan CA, Collins VR, Frydenberg M et al (2014) Androgen deprivation therapy complicaions. Endocr Relat Cancer 21:T119–T129

    Article  CAS  PubMed  Google Scholar 

  7. Smith MR, Finkelstein JS, McGovern FJ et al (2002) Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87:599–603

    Article  CAS  PubMed  Google Scholar 

  8. Shirai K, Hiruta N, Song M et al (2011) Cardio-ankle vascular index (CAVI) as a novel indicator of arterial stiffness: theory, evidence and perspectives. J Atheroscler Thromb 18:924–938

    Article  PubMed  Google Scholar 

  9. Nagayama D, Ohira M, Saiki A et al (2014) Sarpogrelate hydrochloride decreases cardio-ankle vascular index accompanied by increased serum lipidprotein lipase mass in type 2 diabetic patients. Int Heart J 55:337–341

    Article  CAS  PubMed  Google Scholar 

  10. Shirai K, Song M, Suzuki J et al (2011) Contradictory effects of β1- and α1-adrenergic receptor blockers on cardio-ankle vascular stiffness index (CAVI)—The independency of CAVI from blood pressure. J Atheroscler Thromb 18:49–55

    Article  CAS  PubMed  Google Scholar 

  11. Dobsak P, Soska V, Sochor O et al (2015) Increased cardio-ankle vascular index in hyperlipidemic patients without diabetes or hypertension. J Atheroscler Thromb 22:272–283

    Article  CAS  PubMed  Google Scholar 

  12. Mizuno K, Nakaya N, Teramoto T et al (2012) Usefulness of LDL-C-related parameters to predict cardiovascular risk and effect of pravastatin in mild-to-moderate hypercholesterolemia. J Atheroscler Thromb 19:176–185

    Article  CAS  PubMed  Google Scholar 

  13. Hasegawa M, Rodbard S (1979) Effect of posture on arterial pressure, timing of the arterial sounds and pulse wave velocities in the extremities. Cardiology 64:122–132

    Article  CAS  PubMed  Google Scholar 

  14. Yamabe T, Yoshizawa M, Saijo Y et al (2004) Brachio-ankle pulse wave velocity and cardio-ankle vascular index (CAVI). Biomed Pharmacother 58(Suppl 1):S95–S98

    Article  Google Scholar 

  15. Smith JC, Bennett S, Evans LM et al (2001) The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 86:4261–4267

    Article  CAS  PubMed  Google Scholar 

  16. Dockery F, Bulpitt CJ, Agarwal S et al (2003) Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) 104:195–201

    Article  CAS  Google Scholar 

  17. Dockery F, Bulpitt CJ, Agarwal S et al (2009) Effects of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. J Androl 30:410–415

    Article  CAS  PubMed  Google Scholar 

  18. Deenadayalu VP, White RE, Stallone JN et al (2001) Testosterone relaxes coronary arteries by opening the large-conductance, calcium-activated potassium channel. Am J Physiol Heart Circ Physiol 281:H1720–H1727

    CAS  PubMed  Google Scholar 

  19. Jones RD, English KM, Pugh PJ et al (2002) Pulmonary vasodilatory action of testosterone: evidence of a calcium antagonistic action. J Cardiovasc Pharmacol 39:814–823

    Article  CAS  PubMed  Google Scholar 

  20. Shahani S, Braga-Basaria M, Basaria S (2008) Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab 93:2042–2049

    Article  CAS  PubMed  Google Scholar 

  21. Sağlam, HS, Köse O, Kumsar S et al (2012) Fasting blood glucose and lipid profile alterations following twelve-month androgen deprivation therapy in men with prostate cancer. Sci World J 2012:696329. doi:10.1100/2012/696329

  22. McGrowder DA, Jackson LA, Crawford TV (2012) Prostate cancer and metabolic syndrome: is there a link? Asian Pac J Cancer Prev 13:1–13

    Article  PubMed  Google Scholar 

  23. Mohamedali HZ, Breunis H, Timilshina N et al (2011) Changes in blood glucose and cholesterol levels due to androgen deprivation therapy in men with non-metastatic prostate cancer. Can Urol Assoc J 5:28–32

    Article  PubMed  PubMed Central  Google Scholar 

  24. Saylor PJ, Smith MR (2009) Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 181:1998–2008

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Morote J, Gŏmez-Caamaňo A, Alvarez-Ossorio JL et al (2015) The metabolic syndrome and its components in patients with prostate cancer on androgen deprivation therapy. J Urol 193:1963–1969

    Article  CAS  PubMed  Google Scholar 

  26. Braga-Basaria M, Muller DC, Carducci MA et al (2006) Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. Int J Impot Res 18:494–498

    Article  CAS  PubMed  Google Scholar 

  27. Smith MR, Malkowicz SB, Chu F et al (2008) Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. J Clin Oncol 26:1824–1829

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Torimoto K, Samma S, Kagebayashi Y et al (2011) The effects of androgen deprivation therapy on lipid metabolism and body composition in Japanese patients with prostate cancer. Jpn J Clin Oncol 41:577–581

    Article  PubMed  Google Scholar 

  29. Salvador C, Planas J, Agreda F et al (2013) Analysis of the lipid profile and atherogenic risk during androgen deprivation therapy in prostate cancer patients. Urol Int 90:41–44

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura, Chiba, 285-8741, Japan

    Ryo Oka, Takanobu Utsumi, Takumi Endo, Masashi Yano, Shuichi Kamijima, Naoto Kamiya & Hiroyoshi Suzuki

  2. Seijinkai-Mihama Hospital, 1-1-5 Utase, Mihama-ku, Chiba, Chiba, 261-0013, Japan

    Kohji Shirai

Authors
  1. Ryo Oka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takanobu Utsumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takumi Endo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masashi Yano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shuichi Kamijima
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Naoto Kamiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kohji Shirai
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hiroyoshi Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takanobu Utsumi.

Ethics declarations

Conflict of interest

Hiroyoshi Suzuki has received honoraria and/or research grants from Astellas Pharma Inc., GlaxoSmithKline K., Takeda Pharmaceutical Company Ltd., Astra Zeneca, Novartis Pharma, Daiichi-Sankyo, Sanofi KK., and Janssen.

The following authors have no conflict of interest: Ryo Oka, Takanobu Utsumi, Takumi Endo, Masashi Yano, Shuichi Kamijima, Naoto Kamiya, and Kohji Shirai.

Funding statement

This work was supported by a Grant-in-Aid for Scientific Research (C) from the Ministry of Education, Science, Sports and Culture of Japan (No. 25462503) to Hiroyoshi Suzuki.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Oka, R., Utsumi, T., Endo, T. et al. Effect of androgen deprivation therapy on arterial stiffness and serum lipid profile changes in patients with prostate cancer: a prospective study of initial 6-month follow-up. Int J Clin Oncol 21, 389–396 (2016). https://doi.org/10.1007/s10147-015-0891-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-015-0891-7

Keywords

Search

Navigation